• Rong Hu, Han Yan, Manqing Liu, Li Tang, Wenhua Kong, Zerong Zhu, Pan Liu, Wenjuan Bai, Xuejiao Hu, Jie Ding, Xia Wang, and Nianhua Xie.
• Departments of AIDS Prevention.
• J. Acquir. Immune Defic. Syndr. 2021 Feb 1; 86 (2): 213-218.

BackgroundTo describe the virologic and immunologic outcomes among people living with HIV (PLHIV) coinfected with SARS-CoV-2.SettingWuhan, China.MethodsThirty-five coinfected patients were identified by matching the reported cases in National Notifiable Infectious Disease Report system for COVID-19 and HIV in Wuhan by time of April 19, 2020. Questionnaire-based survey and follow-up with blood sample collection were used to obtain characteristics before COVID-19 and after recovery. Nonparametric Mann-Whitney U test, χ2, or Fisher exact test, Mcnemar test, and Wilcoxon test were conducted.ResultsTwenty of the 35 coinfected patients were identified as asymptomatic/mild/moderate COVID-19 (nonsevere group) and 15 were identified as severe/critical (severe group). The severe and nonsevere group had no differences in demographics, HIV baseline status, the intervals between last tests and follow-up tests for CD4+ cell count and HIV-1 viral load (all P > 0.05). Overall, there was a significantly increased number of coinfected patients with HIV-1 viral load ≥20 copies/mL after recovery (P = 0.008). The median viral load increased significantly after recovery in severe group (P = 0.034), whereas no significant change of HIV-1 viral load was observed in the nonsevere group. Limited change of CD4+ cell count was found (all P > 0.05).ConclusionThe coinfection of SARS-CoV-2 may put PLHIV at greater risk for HIV-1 viral rebound especially for severe/critical COVID-19, whereas it had limited impacts on CD4+ cell count. Whether continuous antiretroviral therapy against HIV infection would have significant impacts on CD4+ cell count among PLHIV coinfected with SARS-CoV-2 needs further research.Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

26 keywords...

hide…